Argon laser trabeculoplasty medical therapy to prevent the intraocular pressure rise associated with argon laser trabeculoplasty

Research output: Contribution to journalArticle

Abstract

A prospective, randomized, investigator-masked, parallel study compared the capability of five different intraocular pressure (IOP) lowering agents to prevent acute IOP elevations following argon laser trabeculoplasty. Two hundred sixy eyes (patients) received either apraclonidine 1% (125 eyes), pilocarpine hydrochloride 4% (37 eyes), timolol maleate 0.5% (35 eyes), dipivefrin 0.1% (32 eyes), or acetazolamide 250 mg (31 eyes) both 1 hour before and immediately following 360-degree argon laser trabeculoplasty. Apraclonidine was the only medication that significantly decreased mean IOP from baseline. Only 4 (3%) of the apraclonidine-treated eyes had IOP rises greater than 5 mm Hg. This frequency was significantly lower than that found in eyes treated with acetazolamide (39%), dipivefrin (38%), pilocarpine (33%), or timolol (32%).

Original languageEnglish (US)
Pages (from-to)31-37
Number of pages7
JournalOphthalmic Surgery
Volume22
Issue number1
StatePublished - 1991
Externally publishedYes

Fingerprint

Trabeculectomy
Argon
Intraocular Pressure
Lasers
Timolol
Acetazolamide
Pilocarpine
Therapeutics
Research Personnel

ASJC Scopus subject areas

  • Ophthalmology

Cite this

@article{d330a02da86a47b08388aad76612618a,
title = "Argon laser trabeculoplasty medical therapy to prevent the intraocular pressure rise associated with argon laser trabeculoplasty",
abstract = "A prospective, randomized, investigator-masked, parallel study compared the capability of five different intraocular pressure (IOP) lowering agents to prevent acute IOP elevations following argon laser trabeculoplasty. Two hundred sixy eyes (patients) received either apraclonidine 1{\%} (125 eyes), pilocarpine hydrochloride 4{\%} (37 eyes), timolol maleate 0.5{\%} (35 eyes), dipivefrin 0.1{\%} (32 eyes), or acetazolamide 250 mg (31 eyes) both 1 hour before and immediately following 360-degree argon laser trabeculoplasty. Apraclonidine was the only medication that significantly decreased mean IOP from baseline. Only 4 (3{\%}) of the apraclonidine-treated eyes had IOP rises greater than 5 mm Hg. This frequency was significantly lower than that found in eyes treated with acetazolamide (39{\%}), dipivefrin (38{\%}), pilocarpine (33{\%}), or timolol (32{\%}).",
author = "Robin, {Alan L.}",
year = "1991",
language = "English (US)",
volume = "22",
pages = "31--37",
journal = "Ophthalmic Surgery Lasers and Imaging Retina",
issn = "2325-8160",
publisher = "Slack Incorporated",
number = "1",

}

TY - JOUR

T1 - Argon laser trabeculoplasty medical therapy to prevent the intraocular pressure rise associated with argon laser trabeculoplasty

AU - Robin, Alan L.

PY - 1991

Y1 - 1991

N2 - A prospective, randomized, investigator-masked, parallel study compared the capability of five different intraocular pressure (IOP) lowering agents to prevent acute IOP elevations following argon laser trabeculoplasty. Two hundred sixy eyes (patients) received either apraclonidine 1% (125 eyes), pilocarpine hydrochloride 4% (37 eyes), timolol maleate 0.5% (35 eyes), dipivefrin 0.1% (32 eyes), or acetazolamide 250 mg (31 eyes) both 1 hour before and immediately following 360-degree argon laser trabeculoplasty. Apraclonidine was the only medication that significantly decreased mean IOP from baseline. Only 4 (3%) of the apraclonidine-treated eyes had IOP rises greater than 5 mm Hg. This frequency was significantly lower than that found in eyes treated with acetazolamide (39%), dipivefrin (38%), pilocarpine (33%), or timolol (32%).

AB - A prospective, randomized, investigator-masked, parallel study compared the capability of five different intraocular pressure (IOP) lowering agents to prevent acute IOP elevations following argon laser trabeculoplasty. Two hundred sixy eyes (patients) received either apraclonidine 1% (125 eyes), pilocarpine hydrochloride 4% (37 eyes), timolol maleate 0.5% (35 eyes), dipivefrin 0.1% (32 eyes), or acetazolamide 250 mg (31 eyes) both 1 hour before and immediately following 360-degree argon laser trabeculoplasty. Apraclonidine was the only medication that significantly decreased mean IOP from baseline. Only 4 (3%) of the apraclonidine-treated eyes had IOP rises greater than 5 mm Hg. This frequency was significantly lower than that found in eyes treated with acetazolamide (39%), dipivefrin (38%), pilocarpine (33%), or timolol (32%).

UR - http://www.scopus.com/inward/record.url?scp=0026016483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026016483&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 31

EP - 37

JO - Ophthalmic Surgery Lasers and Imaging Retina

JF - Ophthalmic Surgery Lasers and Imaging Retina

SN - 2325-8160

IS - 1

ER -